User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells.

Primary tabs

Denmeade, S R Lin, X S Tombal, Bertrand [UCL] Isaacs, J T

BACKGROUND: Caspases are a family of cysteine proteases capable of characteristically cleaving after an aspartic acid residue. Various members of the caspase family (e.g., caspases 8 and 9) have been implicated as critical initiators in the signaling phase, while others (e.g., caspases 3, 6, and 7) have been implicated in the effector or execution phase of apoptosis. Thapsigargin (TG) is capable of inducing cell proliferation-independent apoptosis of prostate cancer cells. This study was undertaken to determine if caspase inhibition can prevent TG- or 5-fluorodeoxyuridine (5-FrdU)-induced apoptosis in prostate cancer cells. METHODS: Caspase activity was evaluated by Western blot analysis of the cleavage of retinoblastoma (Rb) protein, a caspase substrate during TG-induced death of prostate cancer cells. In addition, hydrolysis of caspase-specific fluorescent peptide substrates was assayed in lysates from TG-treated cells. Clonogenic survival assays were performed following treatment of rat AT3 and human TSU-Pr1 prostate cancer cell lines with TG and 5-FrdU in the presence and absence of peptide caspase inhibitors. AT3.1 cells transfected with the crmA gene, encoding a viral protein with caspase-inhibitory activity, were also tested for clonogenic survival following TG and 5-FrdU exposure. RESULTS: During treatment with TG, Rb is first dephosphorylated and then proteolytically cleaved into 100-kDa and 40-kDa forms, indicative of caspase activity. A 6-8-fold increase in class II (i.e., caspases 3, 7, and 10) hydrolysis of the caspase substrate Z-DEVD-AFC was observed after 24 hr of TG or 5-FrdU. AT3 cells expressing crmA (i.e., an inhibitor of caspases 1, 4, and 8) were not protected from apoptosis induced by TG or 5-FrdU. The caspase inhibitors Z-DEVD-fmk (i.e., an inhibitor of caspases 3, 7, and 10) and Z-VAD-fmk (i.e., a general caspase inhibitor) were also unable to protect TSU and AT3 cells from apoptosis induced by TG or 5-FrdU. CONCLUSIONS: Caspase activation may play a role in the downstream effector phase of the apoptotic cascade; however, in this study, caspase inhibition did not prevent the signaling phase of apoptosis induced by two agents with distinct mechanisms of cytotoxicity, TG or 5-FrdU. These results suggest that caspase inhibition by recently described endogenous caspase inhibitors should not lead to development of resistance to TG. A strategy for targeting TG's unique cytotoxicity to metastatic prostate cancer cells is currently under development.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 1999
Journal information "The Prostate" - Vol. 39, no. 4, p. 269-279 (1999)
Peer reviewed yes
Publisher JohnWiley & Sons, Inc. (Hoboken)
issn 0270-4137
e-issn 1097-0045
Publication status Publié
Affiliations UCL - MD/CHIR - Département de chirurgie
UCL - (SLuc) Service d'urologie
MESH Subject Amino Acid Chloromethyl Ketones - pharmacology ; Animals ; Antimetabolites, Antineoplastic - pharmacology ; Apoptosis - drug effects ; Blotting, Western ; Caspases - antagonists & inhibitors ; Cell Survival ; Clone Cells ; Cysteine Proteinase Inhibitors - pharmacology ; Enzyme Inhibitors - pharmacology ; Floxuridine - pharmacology ; Humans ; Male ; Oligopeptides - pharmacology ; Prostatic Neoplasms - enzymology - metabolism ; Rats ; Retinoblastoma Protein - metabolism ; Signal Transduction - drug effects ; Thapsigargin - pharmacology ; Tumor Cells, Cultured
Links
  1. Thompson, Science, 267, 1456 (1995)
  2. Isaacs, Environ Health Perspect, 101, 27 (1993)
  3. Kerr J F R, Wyllie A H, Currie A R, Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics, 10.1038/bjc.1972.33
  4. Eastman, Semin Cancer Biol, 6, 45 (1995)
  5. Zhivotovsky, Exp Cell Res, 221, 404 (1995)
  6. Evan, Science, 281, 1317 (1998)
  7. Ashekenazi, Science, 281, 1305 (1998)
  8. Green, Science, 281, 1309 (1998)
  9. Thornberry, Science, 281, 1312 (1998)
  10. Yagoda, Cancer, 71, 1098 (1993)
  11. Carter, Semin Urol, 6, 262 (1988)
  12. Berges, Clin Cancer Res, 1, 473 (1995)
  13. Thastrup, Proc Natl Acad Sci USA, 87, 2466 (1990)
  14. Furuya, Cancer Res, 54, 6167 (1994)
  15. Lin, Prostate, 33, 201 (1997)
  16. Furuya, Prostate, 25, 301 (1994)
  17. Tombal, Cell Calcium, 25, 19 (1999)
  18. Apoptotic pathways in prostate cancer. In: editor. Programmed cell death: role in disease, pathogenesis, and prevention. Greenwich: JAI Press, Inc., 1999.
  19. Qi, Oncogene, 15, 1207 (1997)
  20. Browne, Cell Death Differ, 5, 206 (1998)
  21. COHEN Gerald M., Caspases: the executioners of apoptosis, 10.1042/bj3260001
  22. Thornberry N. A, The caspase family of cysteine proteases, 10.1093/oxfordjournals.bmb.a011625
  23. Villa, TIBS, 22, 00 (1997)
  24. Marcelli, Cancer Res, 58, 76 (1998)
  25. Marcelli, Cancer Res, 59, 382 (1999)
  26. Bowen, Cancer Res, 58, 3275 (1998)
  27. Zhao, J Biol Chem, 272, 22751 (1997)
  28. Srikanth, Cancer Res, 58, 834 (1998)
  29. Deveraux, EMBO J, 17, 2215 (1998)
  30. Cardone, Science, 282, 1318 (1998)
  31. Miura, Proc Natl Acad Sci USA, 92, 8318 (1995)
  32. Martikainen, Cancer Res, 51, 4693 (1991)
  33. Iizumi, J Urol, 137, 1304 (1987)
  34. Furuya, Endocrinology, 136, 1898 (1995)
  35. Gerlach, Lab Invest, 77, 697 (1997)
  36. Furuya, Clin Cancer Res, 2, 389 (1996)
  37. Knudsen E S, Wang J Y, Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation., 10.1128/mcb.17.10.5771
  38. Chen, Oncogene, 14, 1243 (1997)
  39. Janicke, EMBO J, 15, 6969 (1996)
  40. An, Cancer Res, 56, 438 (1996)
  41. Fan, Oncogene, 12, 1909 (1996)
  42. Thornberry, J Biol Chem, 272, 17907 (1997)
  43. Lazebnik, Nature, 371, 346 (1994)
  44. Kaufmann, Cancer Res, 53, 3976 (1993)
  45. Song, EMBO J, 15, 3238 (1996)
  46. Kothakota, Science, 278, 294 (1997)
  47. Li, Cell, 91, 479 (1996)
  48. Hakem, Cell, 94, 339 (1998)
  49. Kuida, Cell, 94, 325 (1998)
  50. Susin, J Exp Med, 186, 25 (1997)
  51. McConkey, J Biol Chem, 271, 22398 (1996)
  52. Alain-Théophile, Cancer Res, 58, 3066 (1998)
  53. Lazebnik, Proc Natl Acad Sci USA, 92, 9042 (1995)
  54. Takahashi, J Biol Chem, 271, 32487 (1996)
  55. Denmeade, Cancer J Sci Am, 4, 15 (1998)
  56. Thapsigargin analogues for targeting programmed death of androgen-independent prostatic cancer cells. Bioorg Med Chem 1998; in press.
  57. Denmeade, Cancer Res, 57, 4924 (1997)
  58. Denmeade, Cancer Res, 58, 2537 (1998)
Bibliographic reference Denmeade, S R ; Lin, X S ; Tombal, Bertrand ; Isaacs, J T. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells.. In: The Prostate, Vol. 39, no. 4, p. 269-279 (1999)
Permanent URL http://hdl.handle.net/2078.1/22605